TO THE EDITOR

NK cell function has been shown to be associated with atopic dermatitis (AD), with patients with AD usually having decreased circulating numbers of NK cells but increasing lesional skin numbers of NK cells (Kabashima and Weidinger, 2020; Mack et al., 2020; Möbus et al., 2021; Sun et al., 2021). An important regulator of NK cell function are KIR genes, which can have either inhibitory or activating effects on NK cells (Pende et al., 2019). In addition to having a potential role in the pathogenesis of AD, NK cells have also been implicated in the development of preeclampsia and endometriosis. Interactions between maternal uterine NK cells and the extravillous trophoblast, potentially mediated by KIR and HLA-C ligands interactions, can influence the development of preeclampsia and pregnancy outcomes (Hiby et al., 2004). KIR and HLA-C ligands have also been associated with the development of endometriosis (Chou et al., 2020). A recent study revealed that KIR gene variation is associated with AD (Margolis et al., 2021). Because NK cell function and KIR genes appear to be involved in the pathogenesis of AD, preeclampsia, and endometriosis, it is possible that there may be an association between these conditions.

To evaluate whether there is an association between AD with preeclampsia and endometriosis, a retrospective cohort study was performed using the Optum Clinformatics Data Mart (Optum) between January 2016 and July 2020, as well as using the Health Improvement Network (THIN) through February 2015. Patients were identified in Optum through the presence of diagnostic codes for AD (L20x) and either asthma (J45x) or allergic rhinitis (J30x), and in THIN using a previously validated algorithm for this dataset (Abuabar et al., 2017). To evaluate for a potential association with preeclampsia, in Optum, patients with AD were matched with up to five patients without AD, based on age and index date of pregnancy delivery. In THIN, patients with AD were matched with up to five patients without AD patients based on age, practice, and an encounter within ±6 months of the latter of practice registration and diagnosis dates for the patient with AD. Logistic regression was used to examine for differences in the frequency of preeclampsia (O14x) during the first recorded pregnancy. In Optum, preeclampsia was defined as any encounter with a diagnosis code for preeclampsia within 180 days before or 90 days after the delivery date. In THIN, preeclampsia was defined by any diagnosis of preeclampsia within 180 days before or after the first pregnancy code.

To evaluate for a potential association with endometriosis, in Optum, patients with AD were matched 1:1 with patients who were diagnosed with a nevus or seborrheic keratosis, based on age and index date of diagnosis. In THIN, the same matching approach was used as described above. Logistic regression was used to examine for differences in the frequency of endometriosis (N80x). All analyses were restricted to female patients between the ages of 15 and 45 years at the time of the index date. Analyses in Optum were additionally adjusted for follow-up time before and after the index date, and all individuals were required to have at least 1 year of continuous enrollment before and after the index date.

Analyses performed in Optum and THIN were synthesized using random effects meta-analysis. Statistical analyses were performed in Stata 15 (StataCorp, College Station, TX). This study was reported in adherence with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines (von Elm et al., 2007).

Preeclampsia was more common in women with AD than controls in both the Optum (1.59% vs. 1.10%; adjusted odds ratio [aOR] = 1.27, 95% confidence interval [CI] 0.83–1.94) and THIN cohorts (0.74% vs. 0.67%; OR = 1.11, 95% CI = 1.03–1.19), although this association did not reach statistical significance in the Optum cohort (Table 1). In the meta-analysis, there was an association between AD and preeclampsia (OR = 1.11, 95% CI = 1.03–1.19). Endometriosis was more common in women with AD than controls in both the Optum (4.29% vs. 3.00%; aOR = 1.48, 95% CI = 1.24–1.78) and THIN cohorts (1.17% vs. 0.95%; OR = 1.24, 95% CI = 1.20–1.27) (Table 2). In the meta-analysis, there was an association between AD and endometriosis (OR = 1.32, 95% CI = 1.09–1.55).

AD is a common persistent dermatologic illness that often begins in early childhood. Classically, other allergic illnesses have been associated with AD such as asthma, food allergies, and seasonal allergies. In this cohort study, using two administrative databases, we identify an association of AD with preeclampsia and endometriosis. The effect estimates were small but similar in both datasets, revealing the generalizability of this finding. The findings of our work and others support that nonallergic illnesses are also associated

Abbreviations: AD, atopic dermatitis; CI, confidence interval; Optum, Optum Clinformatics Data Mart; THIN, The Health Improvement Network

Accepted manuscript published online XXX; corrected proof published online XXX

Cite this article as: JID Innovations 2022;2:100123
© 2022 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
with AD (Sinaii et al., 2002; Stokholm et al., 2017). Furthermore, the associations with preeclampsia and endometriosis are potentially related to genetic variation in KIR genes and NK cell function, revealing additional immunologic pathways that may be associated with AD (Margolis et al., 2021; Nakimuli et al., 2015).

This study has several strengths, including replicating the findings in two independent datasets from two different countries (United States and United Kingdom). This study is limited in that the Optum cohort was relatively small, limiting power to detect differences in our analysis of preeclampsia. Although we have attempted to mitigate this risk using matched cohorts, there is the potential for unmeasured confounding related to degree of interaction with the healthcare system, race and ethnicity, obesity, and smoking; these variables are all poorly measured in our cohorts, making adjustment unreliable. In addition, because we do not have associated genetic data, we are unable to assess whether KIR gene function may be a key factor in these observed associations. Future studies are needed to replicate our findings further and to examine for potential biologic mediators of these observed associations, including potential interactions with ancestry.

Data availability statement
Data are not available from the authors because this dataset is restricted.

Table 1. Association of Atopic Dermatitis with Preeclampsia

| Optum       | Atopic Dermatitis | Without Atopic Dermatitis |
|-------------|------------------|---------------------------|
| N           | 1,821            | 7,946                     |
| Continuous enrollment prior to index, d, mean (SD) | 1,240 (1,082) | 1,097 (985) |
| Continuous enrollment after index, d, mean (SD) | 630 (304) | 553 (288) |
| Preeclampsia, n (%) | 29 (1.59) | 88 (1.10) |
| OR preeclampsia (95% CI), adj | 1.27 (0.83–1.94) | 0.276 |

THIN

| N           | 142,773          | 515,542                   |
| Preeclampsia, n (%) | 1,067 (0.74) | 3,482 (0.67) |
| OR preeclampsia (95% CI), adj | 1.10 (1.03–1.19) | 0.004 |

Abbreviations: adj, adjusted; CI, confidence interval; d, days; Optum, Optum Clinformatics Data Mart; THIN, The Health Improvement Network

1Adjusted for follow-up time

Table 2. Association of Atopic Dermatitis with Endometriosis

| Optum       | Atopic Dermatitis | Without Atopic Dermatitis |
|-------------|------------------|---------------------------|
| N           | 18,342           | 18,342                    |
| Continuous enrollment prior to index, d, mean (SD) | 1,639 (1,317) | 1,170 (793) |
| Continuous enrollment after index, d, mean (SD) | 709 (253) | 747 (271) |
| Endometriosis, n (%) | 304 (4.3) | 213 (3.0) |
| OR endometriosis preeclampsia (95% CI), adj | 1.48 (1.24–1.78) | 0.001 |

THIN

| N           | 567,557          | 2,295,875                 |
| Endometriosis, n (%) | 6,725 (1.17) | 21,995 (0.95) |
| OR endometriosis (95% CI) | 1.23 (1.08–1.40) | 0.002 |

Abbreviations: adj, adjusted; CI, confidence interval; d, days; Optum, Optum Clinformatics Data Mart; THIN, The Health Improvement Network

1Adjusted for follow-up time

ACKNOWLEDGMENTS
Support for this work was provided by the Penn Skin Biology and Diseases Resource-based Center, funded by National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases grant P30-AR069589 and the University of Pennsylvania Perelman School of Medicine.

John S. Barbieri1,*, Daniel B. Shin2 and David J. Margolis3,4

1Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts, USA; 2Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 3Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; and 4Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA

*Corresponding author

REFERENCES
Abuahara K, Magyari AM, Hoffstad O, Jabbar Lopez ZK, Smeeth L, Williams HC, et al. Development and validation of an algorithm to accurately identify atopic eczema patients in primary care electronic health records from the UK. J Invest Dermatol 2017;137:1635–62.

Chou YC, Chen CH, Chen MJ, Chang CW, Chen PH, Yu MH, et al. Killer cell immunoglobulin-like receptors (KIR) and human leukocyte antigen-C (HLA-C) allor- ecognition patterns in women with endometriosis. Sci Rep 2020;10:4897.

Hiby SE, Walker JJ, O’Shaughnessy KM, Redman CWG, Carrington M, Trowsdale J, et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004;200:957–65.

Kabashima K, Weidinger S. NK cells as a possible new player in atopic dermatitis. J Allergy Clin Immunol 2020;146:276–7.

Mack MR, Brestoff JR, Berrien-Elliott MM, Trier AM, Yang TLB, Mccullen M, et al. Blood natural killer cell deficiency reveals an
immunotherapy strategy for atopic dermatitis. Sci Transl Med 2020;12:eaaay1005.

Margolis DJ, Mitra N, Hoffstad OJ, Kim BS, Monos DS, Phillips EJ. Association of KIR genes and MHC class I ligands with atopic dermatitis. J Immunol 2021;207:1522–9.

Möbus L, Rodriguez E, Harder I, Schwarz A, Wehkamp U, Stolzl D, et al. Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitis. J Allergy Clin Immunol 2021;147:1959–65.e2.

Nakimuli A, Chazara O, Hiby SE, Farrell L, Tukwasibwe S, Jayaraman J, et al. A KIR B centromeric region present in Africans but not Europeans protects pregnant women from pre-eclampsia. Proc Natl Acad Sci USA 2015;112:845–50.

Pende D, Falco M, Vitale M, Cantoni C, Vitale C, Munari E, et al. Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation. Front Immunol 2019;10:1179.

Sinaii N, Cleary SD, Ballweg ML, Nieman LK, Stratton P. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod 2002;17:2715–24.

Stokholm J, Sevelsted A, Anderson UD, Bisgaard H. Pre-eclampsia associates with asthma, allergy, and eczema in childhood. Am J Respir Crit Care Med 2017;195:614–21.

Sun Z, Kim JH, Kim SH, Kim HR, Zhang K, Pan Y, et al. Skin-resident natural killer T cells participate in cutaneous allergic inflammation in atopic dermatitis. J Allergy Clin Immunol 2021;147:1764–77.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453–7.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/